Lisdexamfetamine Dimesylate Capsule Shortage: Current Availability and Manufacturer Updates

What’s in Shortage

Drug Name: Lisdexamfetamine Dimesylate Capsule
Brand Name: LISDEXAMFETAMINE DIMESYLATE
Dosage Form: Capsule (10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg)
Therapeutic Category: Psychiatry
Current Status: Current Shortage
Initial Posting Date: 07/14/2023
Last Updated: 02/04/2026

Which Manufacturers Are Affected

Supply status varies significantly by manufacturer and dosage strength:

• Alvogen: All strengths (10 mg - 70 mg) are currently Available. (Contact: 844-842-8672 / CustomerService-US@alvogen.com)
• Amneal Pharmaceuticals: All presentations (20 mg - 70 mg) are Unavailable due to active ingredient shortages. (Contact: 866-525-7270)
• Elite Laboratories, Inc.: All strengths (10 mg - 70 mg) are under Limited Availability. (Contact: 888-852-6657)
• Sun Pharmaceutical Industries, Inc.: All strengths (10 mg - 70 mg) are under Limited Availability, with additional supply anticipated in Q1 2026. (Contact: 800-818-4555)
• SpecGx LLC: All strengths (10 mg - 70 mg) are under Limited Availability and are being placed on allocation to customers. (Contact: 800-325-8888)
• Teva Pharmaceuticals USA, Inc.: Status varies by strength. Some are available, while others are under limited availability with estimated recovery dates in February or March 2026. (Contact: 800-545-8800)
• Lannett Company, Inc.: Mixed status. Some strengths (50 mg, 60 mg) are available, while others (10 mg, 70 mg) are unavailable or limited. (Contact: 844-834-0530)
• Mylan Pharmaceuticals Inc. (Viatris): Mixed status. Strengths 10 mg, 30 mg, 50 mg, and 70 mg are available; 20 mg, 40 mg, and 60 mg are unavailable. (Contact: 800-796-9526)

Why There’s a Shortage

Several manufacturers, including Amneal and Mylan, have cited a shortage of an active ingredient as the reason for supply disruptions. Other manufacturers have reported limited availability or customer allocation without specifying a primary cause. Recovery for several impacted lines is estimated for the first quarter of 2026.

What Patients Should Do

If you are affected by this shortage, please consider the following steps:

• Consult Your Healthcare Provider: Discuss your treatment plan and potential alternatives with your doctor. Do not make changes to your medication without medical supervision.
• Speak with Your Pharmacist: Pharmacists may have information on which specific strengths or manufacturers are currently in stock at their location.
• Contact Manufacturers: You may use the contact information provided above to inquire about the availability of specific National Drug Codes (NDCs).

Disclaimer: This information is for educational purposes only. Patients should always consult with their healthcare provider regarding medical decisions and treatment options.

Source

FDA Drug Shortage Database